Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, H2 2012

Published by: Global Markets Direct

Published: Oct. 31, 2012 - 54 Pages

Table of Contents

Introduction

Global Markets Direct Report Coverage

Systemic Juvenile Idiopathic Arthritis (SJIA) Overview

Therapeutics Development

An Overview of Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA)

Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Development by Companies

Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Investigation by Universities/Institutes

Late Stage Products

Comparative Analysis

Mid Clinical Stage Products

Comparative Analysis

Pre-Clinical Stage Products

Comparative Analysis

Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Products under Development by Companies

Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Products under Investigation by Universities/Institutes

Companies Involved in Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Development

Johnson & Johnson

Protalix BioTherapeutics, Inc.

XOMA Ltd.

Italfarmaco S.p.A.

Avesthagen Limited

Systemic Juvenile Idiopathic Arthritis (SJIA) – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

anakinra - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rilonacept - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ITF-2357 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

golimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Drug Profile Updates

Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Dormant Products

Systemic Juvenile Idiopathic Arthritis (SJIA) – Product Development Milestones

Featured News & Press Releases

Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Abbott's Humira

Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012

May 29, 2012: Abbott To Present Clinical Data On HUMIRA At Annual Meeting Of European League Against Rheumatism

Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis

Sep 28, 2011: Abbott Japan And Eisai Announce Launch Of Humira Prefilled Syringe 20mg/0.4mL

Jul 01, 2011: Abbott And Eisai Receive Japanese Approval For Additional Indication And New Formulation Of Humira In Juvenile Idiopathic Arthritis

Nov 08, 2010: Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA

Oct 18, 2010: Roche Submits ACTEMRA/RoACTEMRA Supplemental Marketing Authorizations In US And Europe For Treatment Of Systemic Juvenile Idiopathic Arthritis

Aug 30, 2010: Abbott Japan and Eisai Submit Application for Additional Indication of Humira, a Fully Human Anti-TNFalpha Monoclonal Antibody, for the Treatment of Juvenile Idiopathic Arthritis in Japan

Jun 15, 2010: TxCell Successfully Completes Preclinical Development of TX-RAD in Inflammatory Arthritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products Under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), H2 2012

Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) – Comparative Analysis, H2 2012

Number of Products under Development by Companies, H2 2012

Number of Products under Investigation by Universities/Institutes, H2 2012

Comparative Analysis by Late Stage Development, H2 2012

Comparative Analysis by Mid Clinical Stage Development, H2 2012

Comparative Analysis by Pre-Clinical Stage Development, H2 2012

Products under Development by Companies, H2 2012

Products under Investigation by Universities/Institutes, H2 2012

Johnson & Johnson, H2 2012

Protalix BioTherapeutics, Inc., H2 2012

XOMA Ltd., H2 2012

Italfarmaco S.p.A., H2 2012

Avesthagen Limited, H2 2012

Assessment by Monotherapy Products, H2 2012

Assessment by Stage and Route of Administration, H2 2012

Assessment by Stage and Molecule Type, H2 2012

Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Drug Profile Updates

Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Dormant Products

List of Figures

Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), H2 2012

Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) – Comparative Analysis, H2 2012

Products under Development by Companies, H2 2012

Products under Investigation by Universities/Institutes, H2 2012

Late Stage Products, H2 2012

Mid Clinical Stage Products, H2 2012

Pre-Clinical Stage Products, H2 2012

Assessment by Monotherapy Products, H2 2012

Assessment by Route of Administration, H2 2012

Assessment by Stage and Route of Administration, H2 2012

Assessment by Molecule Type, H2 2012

Assessment by Stage and Molecule Type, H2 2012

Abstract

• A snapshot of the global therapeutic scenario for Systemic Juvenile Idiopathic Arthritis (SJIA).
• A review of the Systemic Juvenile Idiopathic Arthritis (SJIA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

• Identify and understand important and diverse types of therapeutics under development for Systemic Juvenile Idiopathic Arthritis (SJIA).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.